Mark L. Nelson, Ph.D. Email and Phone Number
Mark L. Nelson, Ph.D. work email
- Valid
- Valid
- Valid
Mark L. Nelson, Ph.D. personal email
Organic and Medicinal Antibiotic and Chemist and Inventor with over 40 patents and marketed drugs Nuzyra and Seysara FDA approved in 2018. From this work I received the ACS Heroes of Chemistry Award in 2019. Now in commercial business development of small molecules for medicine and mankind- I walk in both Worlds now! I've recently joined Piramal Pharma Solutions as Senior Business Development manager in Drug Discovery Chemistry and Biology, US Western States and Canada, providing chemical synthesis services to Pharma and commercial industries in cancer, neurodegeneration and inflammation, and providing advanced synthesis services to the pharmaceutical, optical, synthesis reagent, medical chemical industries and with emphasis on chemical synthesis and chemical library design.If we have have met over the years you know how I love chemical synthesis, drug discovery, and creating drugs- these are all the hallmarks of Piramal Pharma Solutions and we will help you deliver the next waves of drugs for medicine and mankind. Who Are You Going to Trust with Your Science?With Altoris, Inc- a premier cheminformatics group in San Diego, we developed screening and synthesis libraries for chemical diversity HTS, building block synthesis and IP expansion, and used SBDD to provide NCEs for chemical discovery and development in cancer and inflammation targets. While I have been studying the antiinflammatory activity of novel tetracyclines against stroke and neurodegeneration and the links between infectious diseases, mitochondria, and inflammation with researchers worldwide, past and ongoing projects are being led by my colleagues will continue through their labs.Marc Halterman, MD, PhD. Laboratory- University of Buffalo: Tetracyclines for Stroke and cardiovascular diseaseAndrew Dillin/David Raulet Laboratories, UC Berkeley: Compounds affecting cancer and mitohormesis mechanismsNeumedics, Inc.: Compounds active in Macular Degeneration and eye inflammation.Bunick Laboratroy: Yale University- Cryo-EM and SBDD of Novel Compounds Affecting InflammationAuwerx Laboratory EPFL: Novel compounds affecting disease tolerance, mitohormesis and Alzheimer's Disease states. Organic and Medicinal Chemist with Expertise in Business Development and Commercialization of Drugs, Microbiology, Drug Discovery, Antibiotics and the Tetracyclines now heading Business and Science Development, creating compounds, collaborations, and compound collections for drug discovery. Inventor of FDA Approved Nuzyra/Omadacycline and over 40 other patents.
Altoris, Inc.
View- Website:
- altoris.com
- Employees:
- 4
-
Vice President Of Chemistry And Business DevelopmentAltoris, Inc.San Diego, Ca, Us
-
Business DevelopmentPiramal Pharma Solutions Mar 2024 - PresentLexington, Ky, Us -
Vice President Of Chemistry And Business DevelopmentAltoris, Inc. Oct 2016 - PresentUsing Altoris proprietary cheminformatic software to provide HTS compounds, unique collections, and APIs for pharmaceutical, academic, and government health science research. We know where every molecule on the planet is, who produces the best compounds reliably, and design diversity and targeted screening collections for phenotypic screening and discovery against biological targets and diseases.Using SARVision for SBDD against cancer, metabolism, antiinfective, and inflammation targets in conjunction with modeling and crystallographic data.
-
Executive Vp And Co-FounderNeumedics, Inc Feb 2015 - PresentHead chemistry and formulation efforts for Neumedics ophthalmic delivery platform using chemically modified non-antibiotic tetracyclines for degenerative diseases of the eye, including and targeting macular edema and neuroinflammation. Compound NM108 and now NM320 are in preclinical testing demonstrating exceptional properties against ocular inflammation in animal models.
-
Vice President Business And Science DevelopmentCp Lab Chemicals Jun 2022 - Oct 2023
-
Vice President Of Business And Science DevelopmentFrontier Scientific And Subsidiaries, Echelon Biosciences And Frontier Scientific Services, Inc. Oct 2011 - Jun 2022Our companies are leaders in advanced discovery chemicals, reagents, bioassay development and compound management for the pharmaceutical and health care research industry. Our laboratories produce medically important and commercially available chemicals as well as conduct drug discovery research in the fields of cancer, neuroinflammation and antimicrobial chemotherapy.Our laboratories in Delaware, Frontier Scientific Services, Inc, curate, maintain and distribute compounds for the Pharmaceutical industry, with over 20M compounds. We also maintain and are growing the largest repository of molecules for the chemical industry, with over 150K compounds in over 500 separate chemical families, all for the chemical research industry.Recently we have acquired two companies, California Peptide Research, Inc, formerly of Napa, CA, and now produce over 800 research peptides and have also recently launched Frontier Agricultural Sciences, Inc, Newark, DE, providing insect species for biological testing under USDA guidelines and as bioreactors for medically important products.TETRACYCLINE RESEARCH1) We also have a well-established research program in Citrus Greening, aka HuanglongBing, a disease devastating citrus groves worldwide, and have in field and greenhouse studies agricultural compounds directed at this pest funded by the Citrus Research and Development Foundation and studied in conjunction with the USDA and the University of Florida. 2) Stroke Research and Ischemia- Using novel compounds we are blocking ischemia and neurodegeneration at the molecular level in animal models. This research is under a collaborative agreement ongoing with Dr. Marc Halterman, University of Rochester, and funded by the Department of Defense.
-
Senior Director Of ChemistryParatek Pharmaceuticals 1996 - 2011Boston, Ma, UsIn synthesis that began at Tufts University School of Medicine, we created over 3K new derivatives of the tetracycline family of chemotherapeutics that resulted in clinical compounds progressing towards commercialization. This work resulted in over 40 US patents and over 400$MM invested primarily by foreign and national private and institutional investors. From these efforts we invented and generated Omadacycline, now named Nuzyra, a potent antibiotic against drug resistant microbes, and the chemistry of Sarecycline, both compounds that were approved by the FDA against resistant Staph, VRE and Gram negative pathogens, CAP and is active orally. Both compounds are available now worldwide, and was recently the subject of a 330M$ BARDA grant to further study Nuzyra against Anthrax and to be placed in the strategic National Stockpile. Paratek was traded under NSDQ: PRTK then purchased by Novo Holdings and Gurnet Point for 460M$ in 2023. -
Adjunct Professor- BiochemistryRivier University 1996 - 2011Nashua, Nh, UsTaught Biochemical principles at the University level. -
Adjunct Professor- Medicinal Chemistry And Drug DesignTufts University School Of Medicine 1995 - 2005Medford, Massachusetts, UsTaught Medicinal Chemistry principles in the Department of Biochemistry, Professor Bill Bachovchin, Co-lecturer
Mark L. Nelson, Ph.D. Skills
Mark L. Nelson, Ph.D. Education Details
-
Tufts UniversityPost-Doctoral Fellow- Dr. Stuart B Levy -
Gannon UniversityChemistry And Microbiology
-
Temple UniversityMedicinal And Pharmaceutical Chemistry
Frequently Asked Questions about Mark L. Nelson, Ph.D.
What company does Mark L. Nelson, Ph.D. work for?
Mark L. Nelson, Ph.D. works for Altoris, Inc.
What is Mark L. Nelson, Ph.D.'s role at the current company?
Mark L. Nelson, Ph.D.'s current role is Vice President of Chemistry and Business Development.
What is Mark L. Nelson, Ph.D.'s email address?
Mark L. Nelson, Ph.D.'s email address is mn****@****inc.com
What schools did Mark L. Nelson, Ph.D. attend?
Mark L. Nelson, Ph.D. attended Tufts University, Gannon University, Temple University.
What are some of Mark L. Nelson, Ph.D.'s interests?
Mark L. Nelson, Ph.D. has interest in Bioarcheology And Paleobiology, Non Antibioitic Uses Of Antibiotics.
What skills is Mark L. Nelson, Ph.D. known for?
Mark L. Nelson, Ph.D. has skills like Drug Discovery, Medicinal Chemistry, Organic Synthesis, Biochemistry, Drug Design, Pharmaceutical Industry, Commercialization, Life Sciences, Organic Chemistry, Laboratory, Biotechnology, Hplc.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial